ModlinI.M., SandorA.. An analysis of 8305 cases of carcinoid tumors.Cancer.1997; 79: 813–829.
2.
MoertelC.G.. Karnofsky memorial lecture: an odyssey in the land of small tumors.J Clin Oncol.1987; 5: 1502–1522.
3.
TomassettiP., MiglioriM., SimoniP.. Diagnostic value of plasma chromogranin A in neuroendocrine tumours.Eur J Gastroenterol Hepatol.2001; 13: 55–58.
4.
StridsbergM., ObergK., LiQ.. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.J Endocrinol.1995; 144: 49–59.
5.
KvolsL.K., MoertelC.G., O'ConnellM.J.. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue.N Engl J Med.1986; 315: 663–666.
6.
KvolsL.K., BuckM., MoertelC.G.. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).Ann Intern Med.1987; 107: 162–168.
7.
RubinJ., AjaniJ., SchirmerW.. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.J Clin Oncol.1999; 17: 600–606.
MasonR.A., SteaneP.A.. Carcinoid syndrome: its relevance to the anaesthetist.Anaesthesia.1976; 31: 228–242.
10.
LundinL., NorheimI., LandeliusJ.. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities.Circulation.1988; 77: 264–269.
11.
RobiolioP.A., RigolinV.H., WilsonJ.S.. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.Circulation.1995; 92: 790–795.
12.
DenneyW.D., KempWEJr, AnthonyL.B.. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease.J Am Coll Cardiol.1998; 32: 1017–1022.
13.
MoertelC.G.. Treatment of the carcinoid tumor and the malignant carcinoid syndrome.J Clin Oncol.1983; 1: 727–740.
14.
RossE.M., RobertsW.C.. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease.Am J Med.1985; 79: 339–354.
15.
WilkowskeM.A., HartmannL.C., Mul-lanyC.J.. Progressive carcinoid heart disease after resection of primary ovarian carcinoid.Cancer.1994; 73: 1889–1991.
16.
PellikkaP.A., TajikA.J., KhandheriaB.K.. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients.Circulation.1993; 87: 1188–1196.
17.
ConnollyH.M., SchaffH., MullanyC.. Valvular operations for left sided carcinoid heart disease.Circulation.2000; 102: II–462.
18.
ConnollyH.M., NishimuraR.A., SmithH.C.. Outcome of cardiac surgery for carcinoid heart disease.J Am Coll Cardiol.1995; 25: 410–416.
19.
McGuireM.R., PughD.M., DunnM.I.. Carcinoid heart disease: restrictive cardiomyopathy as a late complication.J Kans Med Soc.1978; 79: 661–662, 665.
PandyaU., PellikkaP., SaranoM.. Metastatic carcinoid tumor in the heart: echocardiographic-pathologic study of 11 patients.Circulation.2000; 102: II–542.
23.
RobertsW.C.. A unique heart disease associated with a unique cancer: carcinoid heart disease.Am J Cardiol.1997; 80: 251–256.
24.
ConnollyH.M., SchaffH., NishimuraR.. Cardiac surgery for carcinoid heart disease.Circulation.1997; 96: I2840.
Knott-CraigC.J., SchaffH.V., MullanyC.J.. Carcinoid disease of the heart. Surgical management of ten patients.J Thorac Cardiovasc Surg.1992; 104: 475–481.
28.
RidkerP.M., ChertowG.M., KarlsonE.W.. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease.Am Heart J.1991; 121: 1835–1838.
ThorburnC.W., MorganJ.J., ShanahanM.X.. Long-term results of tricuspid valve replacement and the problem of prosthetic valve thrombosis.Am J Cardiol.1983; 51: 1128–1132.
31.
OckertD., WhiteR.. Anesthetic management of patients with carcinoid heart disease undergoing cardiac surgery: two case reports and a review of previous experience.J Cardiothorac Anesth.1988; 2: 658–665.